NAC & Liver Health

NAC is the FDA-approved antidote for acetaminophen (paracetamol) overdose — the most common cause of acute liver failure in the United States and the United Kingdom. Administered within the first 8–10 hours, NAC essentially eliminates mortality in what would otherwise be a fatal poisoning. Beyond this single flagship indication, the past 15 years have produced a sequence of compelling trials showing that NAC also improves survival in non-acetaminophen acute liver failure, reduces 1-month mortality in severe alcoholic hepatitis from 24% to 8% when combined with corticosteroids, and produces modest benefit in non-alcoholic fatty liver disease (NAFLD/NASH). This article covers the full liver-health literature.

Table of Contents

  1. Acetaminophen Overdose: The Canonical Use
  2. Non-Acetaminophen Acute Liver Failure (ALF)
  3. Severe Alcoholic Hepatitis
  4. NAFLD and NASH
  5. Drug-Induced Liver Injury (DILI)
  6. Viral Hepatitis B and C
  7. Hepatic Ischemia-Reperfusion and Liver Transplant
  8. Cholestasis and PBC
  9. Dosing Summary
  10. Safety and Adverse Effects
  11. References
  12. Connections
  13. Featured Videos

Acetaminophen Overdose: The Canonical Use

NAPQI and Glutathione Depletion

At therapeutic doses, ~90% of ingested acetaminophen is conjugated (via glucuronidation and sulfation) and excreted renally. A small fraction is oxidized by cytochrome P450 (mostly CYP2E1) to a reactive electrophilic metabolite called N-acetyl-p-benzoquinone imine (NAPQI). Normally NAPQI is rapidly neutralized by conjugation with hepatic glutathione. In overdose, the safer pathways saturate, more drug is shunted through CYP2E1, and glutathione is depleted faster than it can be replenished. Once glutathione falls below ~30% of baseline, NAPQI covalently binds cysteine residues on hepatocyte proteins — particularly in centrilobular mitochondria — triggering mitochondrial permeability transition, ATP collapse, and massive centrilobular necrosis.

NAC rescues the liver through two mechanisms. First, it supplies the cysteine needed to regenerate glutathione so NAPQI conjugation can resume. Second, at high concentrations NAC's own thiol can directly substitute for glutathione and scavenge NAPQI.

The Rumack-Matthew Nomogram

Rumack and Matthew published the nomogram in Pediatrics 1975. The US "150 line" begins at 150 micrograms/mL at 4 hours post-ingestion and declines with acetaminophen's half-life (~4 hours). On or above the line indicates probable hepatotoxicity and full NAC treatment. Below the line, NAC is generally unnecessary. The nomogram is only valid for a single acute ingestion with a known time, and levels must be drawn at or after 4 hours.

Mortality and Efficacy

Before NAC, acetaminophen overdose with AST peaks above 1,000 IU/L carried ~5% mortality and up to 20–30% in fulminant cases. NAC given within 8–10 hours reduces hepatotoxicity (ALT/AST >1,000) from ~50% to under 5% and essentially eliminates mortality. Even late NAC — started after 24–36 hours or after established liver injury — improves survival (Keays 1991, BMJ: 48% versus 20%) and reduces cerebral edema.

The 21-Hour IV Prescott Protocol

Originally Prescott 1979 (BMJ), the IV regimen delivers a total of 300 mg/kg over 21 hours:

Many hospitals now use simplified "two-bag" or continuous-infusion protocols (SNAP trial, Bateman 2014, Lancet) that produce fewer dosing errors and fewer anaphylactoid reactions without losing efficacy.

The 72-Hour Oral Smilkstein Protocol

Smilkstein's 1988 NEJM national multicenter study of 2,540 patients established the oral protocol: 140 mg/kg loading, then 70 mg/kg every 4 hours for 17 additional doses (1,330 mg/kg total over 72 hours). Oral NAC is diluted to 5% in juice or soda to mask the rotten-egg odor. Doses are repeated if vomited within 1 hour.

IV Versus Oral

Equivalent efficacy when started within 10 hours. IV is preferred in pregnancy, intractable vomiting, fulminant hepatic failure, or when enteral intake is impossible. Oral is historically preferred in reactive-airway patients to minimize anaphylactoid risk.

Non-Acetaminophen Acute Liver Failure (ALF)

Lee 2009 — The Landmark ALFSG Trial

William Lee and the Acute Liver Failure Study Group published in Gastroenterology 2009 a double-blind placebo-controlled RCT of 173 patients with non-acetaminophen ALF across 24 US centers — etiologies included drug-induced liver injury, autoimmune hepatitis, hepatitis B, and indeterminate causes. Patients received IV NAC (a 72-hour Prescott-style infusion) or placebo.

Key results:

This trial established adjunctive IV NAC as standard of care for adults with non-APAP ALF who present with coma grade I–II. AASLD and EASL guidelines reflect this.

Pediatric ALF — A Negative Trial

Squires 2013 (Hepatology) randomized 184 children with non-APAP ALF to IV NAC or placebo. 1-year survival was actually numerically worse with NAC in the youngest age group. NAC is therefore not recommended in pediatric non-APAP ALF.

Proposed Mechanisms Beyond APAP

Independent of NAPQI scavenging, NAC appears to work in non-APAP ALF through improved systemic and hepatic microcirculation (Harrison 1991, NEJM), antioxidant support against ongoing oxidative injury, reduced cerebral edema via reduced inflammation, and inhibition of neutrophil activation and TNF-alpha signaling.

Severe Alcoholic Hepatitis

Chronic ethanol consumption depletes hepatic mitochondrial glutathione by 40–60%, sensitizing hepatocytes to TNF-alpha-mediated apoptosis — the central lesion in severe alcoholic hepatitis. Adding NAC to the standard corticosteroid backbone has been tested in the landmark Nguyen-Khac trial.

Nguyen-Khac 2011 — NEJM

This French multicenter RCT enrolled 174 patients with biopsy-proven severe alcoholic hepatitis (Maddrey discriminant function ≥ 32) and randomized them to prednisolone 40 mg/day alone versus prednisolone plus IV NAC (the 300 mg/kg Prescott protocol on day 1, then 100 mg/kg/day on days 2–5).

Results:

The STOPAH trial (Thursz 2015, NEJM) confirmed that prednisolone alone has only a modest 28-day survival benefit, which makes the combination with NAC a rational choice for high-risk patients.

NAFLD and NASH

Non-alcoholic fatty liver disease (NAFLD) and its aggressive form non-alcoholic steatohepatitis (NASH) progress through a "multi-hit" model in which hepatic lipid accumulation sensitizes hepatocytes to a second hit of oxidative stress from mitochondrial beta-oxidation, microsomal CYP2E1 induction, and peroxisomal oxidation. NASH livers show depleted glutathione and elevated lipid peroxidation markers (MDA, 4-HNE).

Khoshbaten 2010

This RCT of 30 NAFLD patients comparing NAC 600 mg twice daily to vitamin C 500 mg/day for 3 months showed significantly greater ALT reduction with NAC (from 66 to 39 IU/L, Hepat Mon).

Oliveira 2008

12-month open-label combination of NAC 600 mg BID plus metformin 850 mg BID in NASH patients produced normalization of ALT and improvement in steatosis and inflammation on follow-up biopsy.

NAC Plus Vitamin E

The PIVENS trial (Sanyal 2010, NEJM) established vitamin E 800 IU/day as benefitting NASH histology. NAC complements vitamin E mechanistically: vitamin E scavenges lipid-peroxyl radicals and the resulting tocopheroxyl radical is reduced back to vitamin E by glutathione — which NAC supplies substrate for. Several small trials of the combination show additive effects.

Current Status

No large phase-3 histology-confirmed RCT of NAC monotherapy for NASH has been completed. AASLD guidance does not yet recommend NAC outside trials. Effect sizes are modest (ALT reductions of 25–40%), comparable to other antioxidants.

Drug-Induced Liver Injury (DILI)

Many hepatotoxic drugs (isoniazid, valproate, halothane, amiodarone, methotrexate, platinum-based chemotherapy) generate reactive intermediates detoxified by glutathione. NAC is therefore a mechanistically reasonable rescue.

Baniasadi 2010 — Antituberculous DILI Prophylaxis

60 patients over 60 years old starting anti-TB therapy were randomized to NAC 600 mg twice daily versus placebo for 2 weeks prophylactically. Zero DILI events occurred in the NAC arm versus 37.5% in the placebo arm (p<0.001). This remarkable result has not been widely replicated, but it is striking enough that some clinicians extrapolate to high-risk DILI prophylaxis.

Lee 2009 DILI Subgroup

The 45 DILI patients in the Lee ALFSG trial had particularly strong transplant-free survival benefit from NAC (58% versus 27%) — the largest subgroup effect in the study.

AASLD (2014) and EASL (2019) consider NAC reasonable for severe non-APAP DILI progressing toward acute liver failure, extrapolating from the Lee trial.

Viral Hepatitis B and C

Chronic HCV and HBV cause oxidative stress and glutathione depletion. Pre-DAA-era trials combined NAC with interferon:

In the direct-acting antiviral (DAA) era, NAC is obsolete for HCV treatment itself but may still have a role in patients with advanced fibrosis and ongoing oxidative injury.

Hepatic Ischemia-Reperfusion and Liver Transplant

Cold preservation and warm reperfusion during liver transplantation generate a ROS burst, Kupffer cell activation, and neutrophil infiltration. NAC given to donors, during graft preservation, or to recipients has been studied to reduce primary graft non-function.

Meta-analyses suggest a trend toward reduced early allograft dysfunction with donor NAC but heterogeneous protocols prevent firm recommendations.

Cholestasis and Primary Biliary Cholangitis (PBC)

Evidence is thin. Small open-label studies of NAC in PBC patients not responding to ursodeoxycholic acid have shown modest ALP and GGT reductions but no histologic or survival data. NAC is not part of any cholestatic liver disease guideline. Obeticholic acid and fibrates (BEZURSO trial) are the second-line therapies.

Dosing Summary

Indication Route Regimen
Acetaminophen overdose — Prescott IV IV 150 mg/kg over 60 min → 50 mg/kg over 4 h → 100 mg/kg over 16 h (300 mg/kg / 21 h)
Acetaminophen overdose — Smilkstein oral PO 140 mg/kg load → 70 mg/kg every 4 h x 17 doses (1,330 mg/kg / 72 h)
Non-APAP ALF (Lee protocol) IV 150 mg/kg over 1 h → 12.5 mg/kg/h x 4 h → 6.25 mg/kg/h x 67 h
Severe alcoholic hepatitis (adjunct) IV Day 1: 300 mg/kg Prescott; Days 2–5: 100 mg/kg/day
NAFLD / NASH PO 600 mg BID to 600 mg TID x 3–12 months
Anti-TB DILI prophylaxis PO 600 mg BID x 2 weeks
General hepatoprotection PO 600–1,800 mg/day divided BID–TID

Oral bioavailability is 6–10% because of first-pass deacetylation, but this is irrelevant for liver applications — the liver is the first tissue to see the cysteine released from oral NAC, so hepatic glutathione recovery is actually favored by the oral route.

Safety and Adverse Effects

IV Anaphylactoid Reactions

10–20% of IV courses involve flushing, urticaria, pruritus, angioedema, bronchospasm, or (rarely) hypotension. These are non-IgE-mediated histamine-release reactions concentrated during the first loading dose infusion. Asthmatic patients are at higher risk. Management: pause the infusion, give diphenhydramine, resume at a slower rate. The two-bag and Scottish protocols halve reaction rates.

Oral Side Effects

Nausea, vomiting, diarrhea in 30–50% — driven by the sulfurous taste. Anti-emetics (ondansetron, metoclopramide) and dilution to 5% in cola or juice are standard. If vomiting occurs within 1 hour of a dose, repeat it.

Pregnancy

FDA Category B. NAC crosses the placenta and protects the fetus in maternal acetaminophen overdose — IV NAC is standard of care in pregnancy. No teratogenic signal across decades of use.

Drug Interactions

References

  1. Rumack BH, Matthew H. Acetaminophen poisoning and toxicity. Pediatrics 1975;55(6):871–876. PMID 1134886.
  2. Prescott LF, Illingworth RN, Critchley JA, et al. IV acetylcysteine: the treatment of choice for paracetamol poisoning. BMJ 1979;2(6198):1097–1100. PMID 519312.
  3. Smilkstein MJ, Knapp GL, Kulig KW, Rumack BH. Efficacy of oral NAC in the treatment of acetaminophen overdose. NEJM 1988;319(24):1557–1562. PMID 3059186.
  4. Keays R, Harrison PM, Wendon JA, et al. IV acetylcysteine in paracetamol-induced fulminant hepatic failure: a prospective controlled trial. BMJ 1991;303(6809):1026–1029. PMID 1954453.
  5. Harrison PM, Wendon JA, Gimson AE, Alexander GJ, Williams R. Improvement by acetylcysteine of hemodynamics and oxygen transport in fulminant hepatic failure. NEJM 1991;324(26):1852–1857. PMID 1904133.
  6. Lee WM, Hynan LS, Rossaro L, et al. IV NAC improves transplant-free survival in early stage non-APAP acute liver failure. Gastroenterology 2009;137(3):856–864. PMID 19524577.
  7. Squires RH, Dhawan A, Alonso E, et al. IV NAC in pediatric patients with non-APAP ALF. Hepatology 2013;57(4):1542–1549. PMID 22886633.
  8. Nguyen-Khac E, Thevenot T, Piquet MA, et al. Glucocorticoids plus NAC in severe alcoholic hepatitis. NEJM 2011;365(19):1781–1789. PMID 22070475.
  9. Bateman DN, Dear JW, Thanacoody HKR, et al. Reduction of adverse effects from IV acetylcysteine treatment (SNAP). Lancet 2014;383(9918):697–704. PMID 24315520.
  10. Khoshbaten M, Aliasgarzadeh A, Masnadi K, et al. NAC improves liver function in NAFLD. Hepat Mon 2010;10(1):12–16. PMID 22308119.
  11. Oliveira CP, Stefano JT, de Siqueira ER, et al. NAC and metformin improve histological steatosis and fibrosis in NASH. Hepatol Res 2008;38(2):159–165. PMID 17655731.
  12. Baniasadi S, Eftekhari P, Tabarsi P, et al. Protective effect of NAC on antituberculosis drug-induced hepatotoxicity. Eur J Gastroenterol Hepatol 2010;22(10):1235–1238. PMID 20461008.
  13. Sanyal AJ, Chalasani N, Kowdley KV, et al. Pioglitazone, vitamin E, or placebo for NASH (PIVENS). NEJM 2010;362(18):1675–1685. PMID 20427778.
  14. Thursz MR, Richardson P, Allison M, et al. Prednisolone or pentoxifylline for alcoholic hepatitis (STOPAH). NEJM 2015;372(17):1619–1628. PMID 25901427.
  15. Grant PR, Black A, Garcia N, Prieto J, Garson JA. NAC plus interferon-alpha for chronic hepatitis C. Dig Dis Sci 1997;42(7):1414–1421. PMID 9246038.
  16. D'Amico F, Vitale A, Piovan D, et al. NAC during liver procurement: RCT. Liver Transpl 2013;19(2):135–144. PMID 23172830.
  17. Hu J, Zhang Q, Ren X, Sun Z, Quan Q. NAC in non-APAP ALF: a meta-analysis. Clin Res Hepatol Gastroenterol 2015;39(5):594–599. PMID 25770933.
  18. Chughlay MF, Kramer N, Spearman CW, Werfalli M, Cohen K. NAC for non-paracetamol DILI: a systematic review. Br J Clin Pharmacol 2016;81(6):1021–1029. PMID 26757427.
  19. Mumtaz K, Azam Z, Hamid S, et al. NAC in adults with non-APAP ALF without transplantation. Hepatol Int 2009;3(4):563–570. PMID 19727985.
  20. Pamuk GE, Sonsuz A. NAC in the treatment of NASH. J Gastroenterol Hepatol 2003;18(10):1220–1221. PMID 12974919.

Connections

↑ Back to Table of Contents

Video Thumbnail

Acetaminophen Toxicity and NAC — Mechanism

Video Thumbnail

NAC and Liver Protection

Video Thumbnail

Glutathione and NAFLD